A Randomized Phase 3 Study Comparing Pemetrexed Plus Cisplatin With Gemcitabine Plus Cisplatin as First-Line Treatment in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer.

Trial Profile

A Randomized Phase 3 Study Comparing Pemetrexed Plus Cisplatin With Gemcitabine Plus Cisplatin as First-Line Treatment in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2014

At a glance

  • Drugs Cisplatin; Gemcitabine; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Dec 2010 Planned end date changed from 1 Jul 2013 to 1 Nov 2012 as reported by ClinicalTrials.gov.
    • 17 May 2010 Planned end date changed from Sep 2013 to Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top